Asthma Clinical Trial
Official title:
Best Strategies for Implementation of Clinical Pathways in Emergency Department Settings
NCT number | NCT01815710 |
Other study ID # | DCO150GP |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | January 2013 |
Est. completion date | April 13, 2018 |
Verified date | July 2019 |
Source | Children's Hospital of Eastern Ontario |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
An Ontario-wide study to identify best strategies to promote uptake of high quality, expert
developed Clinical Pathways (CPs) within Emergency Departments.
The investigators will work with 16 Community EDs across Ontario to i) tailor an
implementation strategy that works for each ED, ii) assist with the implementation of one
pediatric emergency CP (Asthma or Gastroenteritis) at each site, and iii) evaluate the impact
on health professionals, patient outcomes and economic costs. The investigators will conduct
a 3.5 - year mixed methods health services research project with four study objectives: 1) to
design a theory-based and knowledge user-informed intervention strategy to successfully
implement two provincial pediatric emergency clinical pathways into practice in community
Emergency Departments (EDs); 2) to evaluate the effectiveness of this implementation
strategy; 3) to conduct a process evaluation to assess the implementation strategy; and 4) to
conduct an economic analysis to evaluate implementation costs and benefits.
Status | Completed |
Enrollment | 6330 |
Est. completion date | April 13, 2018 |
Est. primary completion date | April 13, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 3 Months to 17 Years |
Eligibility |
Inclusion Criteria: - Selecting from 149 community EDs in Ontario, we will recruit EDs that do not have a CP in place for either Pediatric Asthma or Pediatric V&D. To minimize contamination between sites, we will request data from Health Force Ontario, an organization that assists with physician coverage at different EDs, to ensure ED physicians are not working at more than one study site. An additional inclusion criterion is commitment to the implementation intervention by an administrative lead on behalf of the hospital. Specific inclusion/exclusion criteria for use with patients have been defined for each CP. - Medical records departments at each site will be asked to pull relevant charts, using International Statistical Classification of Diseases and Related Health Problems (ICD)-10 codes for all diagnoses related to our index conditions (Asthma and with V&D) during the defined study periods. In our experience, this approach has worked successfully with community ED studies. Chart auditors will review all records to ensure eligibility criteria are met. All retrieved and eligible patient charts will be audited. |
Country | Name | City | State |
---|---|---|---|
Canada | Children's Hospital of Eastern Ontario | Ottawa | Ontario |
Lead Sponsor | Collaborator |
---|---|
Children's Hospital of Eastern Ontario | Institute for Clinical Evaluative Sciences, Ottawa Hospital Research Institute |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Completed CP on relevant patient charts. | Our primary process outcome will be a completed CP on relevant patient charts. Each CP will be reviewed to determine required clinical care elements to achieve the CP goals, and completion criteria will be defined to guide determination of one of three grades: 1) initial, with the CP started with little or no documentation; 2) partial, with some but incomplete documentation; or 3) full, meeting sufficient requirements for CP success. Because the busyness of a given shift may affect CP use decisions, a secondary outcome will be CP use for relevant patients, adjusted for shift-level ED data. | 18 months | |
Primary | Received appropriate care based on evidence-based treatments recommended in the CP. | The proportion of pediatric patients with asthma and V&D who received appropriate care based on evidence-based treatments recommended in the CP. | 18 months | |
Secondary | Asthma - PRAM | Asthma CP intervention will include: 1) documentation of a Pre-school Respiratory Assessment Measure (PRAM) score. | 18 months | |
Secondary | V&D - Gorelick and intravenous therapy. | For the V&D CP intervention, secondary clinical outcomes will include: 1) documentation of a Gorelick score for dehydration; and 2) the proportion of children treated with intravenous therapy for rehydration. | 18 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|